Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02641236 · ClinicalTrials.gov registry record · Phase 2
Gut Decontamination In Pediatric Allogeneic Hematopoietic
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02641236 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 24 participants.
The verdict
NCT02641236, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This research study is for participants who are undergoing allogeneic hematopoietic stem cell transplantation (HSCT) and are at risk for developing acute graft-versus-host disease (GVHD). GVHD is a complication of HSCT in which immune cells from the donor cause inflammation and injury to tissues and organs of the HSCT recipient. Vancomycin-polymyxin B (commonly called "vancopoly") is an oral antibiotic that is given to people undergoing allogeneic HSCT as a preventive measure for acute GVHD. This research study is studying the effects of vancopoly on the microorganisms living in the intestine during and after stem cell transplantation.
Interventions
- DRUG Vancomycin-polymyxin B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-03 |
| Est. Completion | 2021-10-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02641236
The ClinicalTrials.gov registry entry for NCT02641236 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vancomycin-polymyxin B is the first listed.
NCT02641236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02641236 about?
NCT02641236 is a clinical study titled "Gut Decontamination In Pediatric Allogeneic Hematopoietic". This research study is for participants who are undergoing allogeneic hematopoietic stem cell transplantation (HSCT) and are at risk for developing acute graft-versus-host disease (GVHD). GVHD is a complication of HSCT in which immune cells from the donor cause inflammation and injury to tissues and...
What is the current status of trial NCT02641236?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-03. Estimated completion is 2021-10-28.
What interventions are being tested in trial NCT02641236?
The interventions under investigation include: Vancomycin-polymyxin B (DRUG).
Who is sponsoring clinical trial NCT02641236?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.